FDA Denies Approval for Patisiran in ATTR Cardiomyopathy

FDA Denies Approval for Patisiran in ATTR Cardiomyopathy

The US Food and Drug Administration (FDA) has declined to approve the RNA interference (RNAi) therapeutic agent patisiran (Onpattro, Alnylam Pharmaceuticals) for treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, the company has announced. ATTR amyloidosis is an underdiagnosed, rapidly progressive,…

Read More